Zhongyuan Union Stem Cell Bio-engineering Corporation provided preliminary earnings guidance for the full year 2014. The company predicts a net profit owned by shareholders of listed company in 2014 to be about RMB 37 million, with an increase of about 412.77% compared with 2013 and the earnings per share being about RMB 0.10.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.93 CNY | +1.26% | -2.59% | -16.48% |
1st Jan change | Capi. | |
---|---|---|
-16.48% | 1.07B | |
-9.00% | 11.67B | |
-4.32% | 8B | |
+6.37% | 5.72B | |
+30.76% | 5.5B | |
-14.91% | 3.84B | |
+11.39% | 2.66B | |
-61.44% | 2.66B | |
-9.76% | 2.3B | |
+17.40% | 2.01B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Zhongyuan Union Stem Cell Bio-Engineering Corporation Provides Preliminary Earnings Guidance for the Full Year 2014